breast cancer

FDA says yes to MedCognetics breast cancer screening AI
Pharmaphorum
Thu, 12/15/22 - 10:53 am
Medtech
digital health
MedCognetics
FDA
artificial intelligence
breast cancer
diagnostics
AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials
Clinical Trials Arena
Mon, 12/12/22 - 10:26 am
AstraZeneca
Daiichi Sankyo
clinical trials
datopotamab deruxtecan
metastatic triple-negative breast cancer
breast cancer
SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
Fierce Pharma
Fri, 12/9/22 - 10:54 am
SABCS
AstraZeneca
Enhertu
breast cancer
Daiichi Sankyo
Roche
Kadcyla
Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate
Fierce Biotech
Fri, 12/9/22 - 10:46 am
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Gilead Sciences
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
BioSpace
Fri, 12/9/22 - 10:36 am
Myriad Genetics
diagnostics
genetic testing
breast cancer
RiskScore
Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial
BioSpace
Wed, 12/7/22 - 11:39 pm
Novartis
Kisqali
breast cancer
clinical trials
Carrick Therapeutics raises $60m for novel cancer treatments, including $35M from Pfizer
Silicon Republic
Fri, 12/2/22 - 11:02 am
Carrick Therapeutics
funding
breast cancer
Pfizer
Google Health licenses breast cancer detection AI to iCAD
Medtech Dive
Tue, 11/29/22 - 10:58 am
Medtech
diagnostics
Google Health
iCAD
artificial intelligence
breast cancer
mammography
The problem with Her2-low testing
EP Vantage
Mon, 11/28/22 - 07:34 pm
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
diagnostics
HER2-low breast cancer
Pfizer's $1B protein degradation bet yields 3% response rate in Arvinas' midphase breast cancer trial
Fierce Biotech
Tue, 11/22/22 - 11:00 am
Pfizer
protein degradation
Arvinas
clinical trials
breast cancer
ARV-471
Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out
Fierce Biotech
Tue, 11/1/22 - 12:09 pm
Pfizer
R&D
NASH
breast cancer
eczema
Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu
Endpoints
Mon, 10/31/22 - 04:15 pm
Daiichi Sankyo
AstraZeneca
Enhertu
breast cancer
non-small cell lung cancer
Anixa begins Phase Ib trial of breast cancer vaccine
Clinical Trials Arena
Thu, 10/27/22 - 10:50 am
Anixa Biosciences
breast cancer
clinical trials
AstraZeneca beats Roche twice in a day
EP Vantage
Wed, 10/26/22 - 10:20 am
AstraZeneca
Roche
SERD
breast cancer
Ipatasertib
capivasertib
Camizestrant
After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review
Fierce Pharma
Tue, 10/11/22 - 04:08 pm
Gilead Sciences
breast cancer
Trodelvy
ESMO
FDA
priority review
To prevent unnecessary biopsies, scientists train an AI model to predict breast cancer risk from MRI scans
Stat
Mon, 10/3/22 - 10:05 am
breast cancer
artificial intelligence
breast scans
diagnostics
Medtech
Olema Oncology previews Phase III trial plans for dual-mechanism SERD in breast cancer
Clinical Trials Arena
Fri, 09/23/22 - 10:57 am
Olema Oncology
SERD
breast cancer
ESMO: Gilead's Trodelvy makes surprise comeback with above-par breast cancer survival showing
Fierce Pharma
Wed, 09/7/22 - 11:59 pm
Gilead Sciences
Trodelvy
ESMO
HR-positive HER-negative breast cancer
breast cancer
Dizal reports positive Phase I data for breast cancer therapy
Clinical Trials Arena
Tue, 09/6/22 - 10:37 am
Dizal Pharmaceutical
clinical trials
breast cancer
HER2-positive metastatic breast cancer
DZD1516
As Sanofi's SERD falls, Menarini’s advances with EU review
Fierce Biotech
Fri, 08/19/22 - 10:42 am
Sanofi
Menarini
Europe
SERD
breast cancer
elacstrant

Pages